Join

Compare · CGC vs PRDS

CGC vs PRDS

Side-by-side comparison of Canopy Growth Corporation (CGC) and Pardes Biosciences Inc. (PRDS): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CGC and PRDS operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
  • CGC is the larger of the two at $2.86B, about 4.4x PRDS ($657.5M).
  • CGC has hit the wire 8 times in the past 4 weeks while PRDS has been quiet.
  • CGC has more recent analyst coverage (19 ratings vs 3 for PRDS).
MetricCGCPRDS
Company
Canopy Growth Corporation
Pardes Biosciences Inc.
Price
$0.95-3.75%
$2.19+1.39%
Market cap
$2.86B
$657.5M
1M return
-7.44%
-
1Y return
-28.32%
-
Industry
Medicinal Chemicals and Botanical Products
Medicinal Chemicals and Botanical Products
Exchange
NYSE
NASDAQ
IPO
2021
News (4w)
8
0
Recent ratings
19
3
CGC

Canopy Growth Corporation

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the mitigation of persistent post-concussion symptoms. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

PRDS

Pardes Biosciences Inc.

Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.

Latest CGC

Latest PRDS